The Evolving Genetic Landscape of Parkinson’s Disease: Global Prevalence, Phenotypic Correlations, and the Precision Medicine Imperative

The Evolving Genetic Landscape of Parkinson’s Disease: Global Prevalence, Phenotypic Correlations, and the Precision Medicine Imperative

This review synthesizes recent large-scale genomic evidence (ROPAD, PD GENEration, MDSGene) to outline the diagnostic yield, ethnic variations, and genotype-phenotype correlations in Parkinson’s disease, emphasizing the transition toward universal genetic testing for clinical trial stratification.
One in Three Older Emergency Admissions Face Cognitive Morbidity: Insights from the ORCHARD-EPR Study

One in Three Older Emergency Admissions Face Cognitive Morbidity: Insights from the ORCHARD-EPR Study

A large-scale cross-sectional study of 51,202 admissions reveals that 35.6% of patients aged 70 and older experience cognitive morbidity, predominantly delirium. The findings underscore the urgent necessity for hospital-wide screening and multidisciplinary geriatric support across nearly all medical and surgical specialties.
Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience

Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience

This study demonstrates that the mismatch between tau burden and clinical symptoms identifies individuals with non-AD copathology or cognitive resilience. These findings offer a precision medicine framework for predicting disease trajectories and monitoring responses to emerging anti-amyloid therapies.
Elevated Cardiac Biomarkers Serve as Early Indicators of Structural Brain Damage and Cognitive Decline: Insights from the Hamburg City Health Study

Elevated Cardiac Biomarkers Serve as Early Indicators of Structural Brain Damage and Cognitive Decline: Insights from the Hamburg City Health Study

The Hamburg City Health Study reveals that elevated NT-proBNP and hs-cTnI are significantly linked to neurodegeneration and vascular brain injury. These cardiac biomarkers offer a non-invasive pathway for identifying patients at high risk for cognitive impairment and structural brain changes.
Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial

Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial

The DANFLU-2 trial demonstrates that high-dose influenza vaccine provides superior protection against influenza-related hospitalizations in chronic kidney disease and reduces cardiorespiratory hospitalizations in older adults irrespective of cardiovascular disease status.
Antiviral Therapy Fails to Slow Alzheimer’s: The VALAD Trial Reveals Unexpected Cognitive Worsening with Valacyclovir

Antiviral Therapy Fails to Slow Alzheimer’s: The VALAD Trial Reveals Unexpected Cognitive Worsening with Valacyclovir

The VALAD randomized clinical trial found that valacyclovir did not improve outcomes in patients with early symptomatic Alzheimer’s and HSV seropositivity. Instead, patients receiving the antiviral showed significantly greater cognitive decline compared to placebo over 78 weeks, cautioning against off-label use.
The Earlier, the Better: INTERACT Pooled Analysis Confirms 3-Hour Golden Window for Intensive Blood Pressure Lowering in Acute ICH

The Earlier, the Better: INTERACT Pooled Analysis Confirms 3-Hour Golden Window for Intensive Blood Pressure Lowering in Acute ICH

A pooled analysis of over 11,000 patients from the INTERACT trials demonstrates that intensive blood pressure reduction significantly improves functional recovery in acute intracerebral hemorrhage, with the most robust benefits observed when treatment is initiated within three hours of symptom onset.
Telemedicine is Superior to Onboard Neurologists for Optimizing Mobile Stroke Unit Efficiency: Results from the MSU-TELEMED Trial

Telemedicine is Superior to Onboard Neurologists for Optimizing Mobile Stroke Unit Efficiency: Results from the MSU-TELEMED Trial

The MSU-TELEMED trial demonstrates that a telemedicine model for mobile stroke units significantly improves neurologist resource utilization while maintaining safety, outperforming the traditional onboard neurologist model in a hierarchical composite outcome despite a minor four-minute treatment decision delay.